Bone marrow histology after bone marrow transplantation has rarely been studied. Here, we reviewed the pre-and post-transplant bone marrow biopsies (BMB) of 40 acute myelogenous leukemia (AML) patients autografted in our center, 28 with normal and 12 with delayed peripheral recovery. The two groups were comparable in terms of previous therapy, disease phase and the number of infused cells, and received the same conditioning regimen. In the former group, reduced bone marrow cellularity and mild reticulin abnormalities were usual histological findings; in the latter, five patients had the same pattern, but the other seven had an almost undetectable hematopoietic parenchyma and severe reticulin derangement. One of these seven patients died of reactivated hepatitis B virus infection; the others eventually achieved peripheral recovery, with none of them experiencing a relapse. Autografted AML patients are excellent subjects for histological investigations. They account for the majority of delayed engraftments, the contribution of extramedullary components to the timing of engraftment is minimal, and leukemia relapse cannot be ruled out. These results suggest that BMB is a useful investigation in the workup of late engraftment. A high degree of reticulin derangement with an almost undetectable hematopoietic parenchyma appear to be the morphological hallmarks of late engraftment. Bone Marrow Transplantation (2000) 25, 837-841.
/l within 1 month of bone marrow transplantation (BMT). [1] [2] [3] In the case of allogeneic transplantation, it is caused by multiple biological events and may lead to graft failure. [4] [5] [6] [7] [8] [9] [10] It occurs less frequently after autografting, because of the extensive use of peripheral blood hematopo- ietic stem cells and hematopoietic growth factors. [11] [12] [13] [14] Most of the cases in this group are acute myelogenous leukemia (AML) patients, who are neither routinely transplanted with peripheral stem cells nor treated with growth factors. [15] [16] [17] [18] Harvesting insufficiencies, and microenvironmental derangement due to previous conventional chemotherapy and conditioning regimens, are the main causes of delayed peripheral recovery. 2, [19] [20] [21] [22] Bone marrow biopsies (BMB) allow a good assessment of cellularity and reticulin, but are not frequently performed during late engraftment, and the results observed in the small series studied so far have been inconclusive. 23 The present aim is to describe bone marrow biopsy findings in a series of AML patients with late engraftment after autologous BMT, and compare them with those observed in AML patients undergoing autografting during the same period but experiencing normal peripheral recovery.
Materials and methods
Over the last 10 years, 12 of the AML patients (six male, six female; median age 39 years: range 25-55) autografted in our center failed to achieve PMN recovery to more than 0.5 ϫ 10 9 /l within 1 month. Eleven patients in first CR had received unpurged autologous BMT as late intensification 8-13 months after diagnosis (median 11 months), and one patient in second CR had received mafosphamide-purged bone marrow. Nine of the patients autografted in first CR had been previously treated with idarubicin-containing regimens; the other two had received daunorubicin. The pretransplant conditioning regimen included Ara-C 3 g/m 2 /12 h on days Ϫ9/Ϫ8, CTX 60 mg/kg/day on days Ϫ6/Ϫ5, and TBI at a total dose of 10 Gy fractionated into equal doses from day Ϫ3 to day Ϫ1. The routine BMB taken before and 1 month after autologous BMT were reviewed and compared with those of 28 other AML patients who underwent autologous BMT and experienced normal peripheral recovery; bone marrow (BM) smears and cytogenetic analyses were also included in the retrospective diagnostic work-up. The two groups were comparable in terms of age, sex, disease phase at BMT and time interval between diagnosis and transplant, and both received the same conditioning regimen. Using routinely stained BM sections, the following histological parameters were investigated as possible indicators of late engraftment: overall cellularity as a percentage of hemopoietic tissue; the pro- Table 1 ) (hematoxylin-eosin).
portion, morphology and maturity of the hematopoietic series; reticulin abnormalities and sinusoid dilation ( Figure 1) ; and the proportion of lymphocytes, plasma cells and eosinophils. Reticulin derangement in Gomori-stained sections was graded as follows: grade 0, no abnormalities; grade I, thickening of reticulin fibres; grade II, fragmentation of the reticulum; grade III, stromal edema ( Figure  2) ; grade IV, collapse and gross distortion.
Between-group differences were analyzed by means of the chi square and the Student's t-test. Relapse, death during CR or drop-out were considered as events: disease-free (DFS) and event-free survival (EFS) curves were calculated according to Kaplan and Meier and compared by means of the log-rank test.
Results
The total number of mononuclear cells infused to patients with late engraftment ranged from 1.04 to 13. Table 1 ) (hematoxylin-eosin). 5 /kg (median 6.83). These differences were not statistically significant.
In the pre-transplant BM specimens of patients with normal engraftment, BM cellularity was normal, reticulin alterations did not exceed grade II (six patients), and hematopoietic cell lineages were normal except for seven cases with slight dysmegakaryocytopoiesis. Karyotypes and BM cytological analyses were normal. One month after BMT, overall bone marrow cellularity was reduced in all cases (hematopoietic parenchyma 5-30%, median 15%), and reticulin derangement did not exceed grade II (seven cases); only rare alterations in the maturity or morphology of the hematopoietic lineages were observed.
In the pre-autologous BMT specimens of patients with delayed engraftment, BM cellularity was normal. The reticulum was grade II in three cases and normal in the others; the hematopoietic cell lineages were normal except for four cases of slight dysmegakaryocytopoiesis; the karyotypes and BM cytologies were normal. In the post-transplant specimens, hematopoietic parenchyma was 10-20% in four cases, between 1% and 5% in two, and less than 1% in six; dyserythropoiesis was found in one case and dysmegakaryocytopoiesis in two. Reticulin derangement was grade I in three cases, grade II in two, and grade III/IV in seven. Of Table 1 ) (hematoxylin-eosin). the seven patients with grade III/IV reticulin abnormalities, BM cellularity was less than 1% in six cases, and between 1% and 5% in one (Figures 3 and 4) . As of 31 August 1998, three of the 28 patients with normal peripheral recovery had died of infection while still in CR, 15 had relapsed 3-64 months (median 12) after autologous BMT, and 10 were still in CR after 78-130 months (median 116).
In the group with delayed engraftment (Table 1) , PMN recovery was achieved 32-84 days after autologous BMT, and platelet recovery after 57-418 days. Two patients had relapsed and one developed a secondary myelodysplastic syndrome 6-12 months after BMT: all three had pre-transplant reticulin anomalies, the degree of which was unchanged in two and decreased in the third post-BMT. Furthermore, the dysmegakaryocytopoiesis present in two of the patients before autografting had disappeared. None of the seven patients with a high degree of post-transplant reticulin derangement had relapsed, but one patient in CR died of reactivated hepatitis B virus infection 6 months after BMT. Eight patients are still in continuous CR 24-126 months (median 57) after autologous BMT.
The median DFS ( Figure 5 ) was 28 months in the group with normal engraftment and had not been reached in the Bone Marrow Transplantation group with delayed engraftment; the 10-year chance of DFS was 40% in the former and 81.5% in the latter group (P ϭ NS).
The median EFS ( Figure 6 ) was 28 months in the group with normal engraftment and had not been reached in the group with delayed engraftment; the 10-year chance of EFS was 40% in the former and 66.5% in the latter group (P ϭ NS).
Discussion
The pathogenetic and biological events of delayed hematological recovery after BMT have been the subject of many reports. [4] [5] [6] [7] [8] [9] [10] 22 However, far less attention has been paid to the search for their possible histological counterparts. 22, 23 This may be considered of questionable interest in allogeneic BMT recipients because graft failure is a complex condition affected by a number of extramedullary factors and hardly related to that occurring after autologous BMT. 5, 10 The available evidence from autologous BMT patients indicates that intrinsic bone marrow factors are the main variables influencing hematopoietic recovery, parti- cularly the quality of harvesting and the degree of microenvironmental derangement. 2, 20, 22 Individual patients with hematological diseases other than AML can be considered unsuitable for a histological review because their clinical heterogeneity and the persistence of extramedullary disease in lymphoproliferative disorders make it more difficult to interpret histological data. 3, 21 However, autografted AML patients are excellent subjects for histological BM investigations since they account for the majority of delayed engraftments and the contribution of extramedullary components to the timing of engraftment is minimal. [15] [16] [17] [18] Moreover, leukemic relapse cannot be ruled out in patients failing to achieve normal peripheral values, and so BMB may help in differentiating this diagnosis from truly delayed engraftment. 15, 22 On the basis of the above considerations, the present series includes only the AML patients who underwent autografting at our center during the last 10 years. The patients with normal and those with delayed peripheral recovery were fully comparable in terms of previous treatment, disease phase, conditioning regimen and the number of infused cells. It is also worth mentioning that all patients had received bone marrow as a source of hematopoietic stem cells, and none had received hematopoietic growth factors at any time during their post-transplant course.
The results of our histological review of autografted AML patients with delayed peripheral recovery revealed two distinct morphological patterns. The histological findings in five of them were indistinguishable from those observed in the patients with normal peripheral recovery, and their clinical outcome was the same, with some experiencing a relapse. The other seven patients had a high degree of reticulin derangement and almost no hematopoietic parenchyma (all had less than 5% and six had less than 1%). Apart from one patient who died of infection, all eventually achieved peripheral recovery and none relapsed.
Our histological findings are different from those observed in four patients by Rosenthal et al, 23 who regularly found some degree of histiocyte proliferation. However, their series included patients with different diagnoses and in different disease phases, and the fact that three had received GM-CSF may have contributed towards the histiocyte proliferation. 24 Our data seem to be more similar to those relating to bone marrow fibrosis and allogeneic BMT, 4 but any further discussion is hindered by the biological differences between autologous and allogeneic BMT.
Our results suggest that differences in pre-transplant variables and the conditioning regimen play a secondary role in determining the timing of engraftment after autologous BMT. The quality of harvesting seems to be of doubtful relevance, since the number of infused CFU-GM was comparable in the patients with normal or delayed peripheral recovery, and ex vivo purging had been performed in only one case. Conversely, the demonstration of a grossly distorted reticulin and almost no hematopoietic parenchyma in the majority of the patients with late engraftment provides some morphological evidence to support other reports indicating the role of microenvironmental factors. 22, 25 However, the reticulin derangement can be considered relatively benign as it does not preclude subsequent engraftment. Furthermore, in our experience, it allows leukemic relapse to be ruled out with some degree of confidence. This favorable outcome conflicts with the findings described in the other papers dealing with histology and late engraftment, a discordance that may once again be explained by the differences between our, and the other series in terms of diagnosis, disease phase and type of transplant. 4, 23 Autografted AML patients represent a subset of transplanted patients who are particularly suitable for histological investigations, as is emphasised by the discussion of selection criteria. The interpretation of post-transplant BMB findings in other settings, is made more difficult by the concurrence of extramedullary events, 3, 21 and similar histological patterns may herald different prognoses. A thorough discussion of the mechanisms underlying the development of severe stromal distortion is beyond the scope of the present paper, but the prevalence of phenomena such as edema, fragmentation and the collapse of reticulin fibres, is more reminiscent of probable therapy-related toxicity rather than reactive events.
In conclusion, BMB is recommended as a useful investigation in the diagnostic and perhaps the prognostic workup of late engraftment in autografted AML patients. Given the satisfactory degree of clinical and histological homogeneity among the cases reported in this paper, the combination of a high degree of reticulin derangement and an almost undetectable hematopoietic parenchyma appear to be the morphological hallmarks of late engraftment.
